Last week, Jeffrey Hubbard, PhD, Head…
Neuroservice wins a 820,000€ grant from the Region “Provence Alpes…
As of November 1st, 2021, Neuroservice and Neuroservice USA officially…
Ketamine has psychotomimetics and antidepressant effects and is a noncompetitive NMDAR antagonist.
Neuroservice is proud to present its brand new facilities in…
Neuroservice supports CNS & Pain research thanks to electrophysiological solutions…
On Monday, July 26, we had the pleasure to welcome…
Drug discovery workflows for neurological indications have traditionally relied on…
MaxWell Biosystems‘ HDMEA technology MaxTwo is on its way to…
